Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Nonhematologic Malignancies 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Recurrent Lung Squamous Cell Carcinoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-hematologic Malignancy 1Neurofibrosarcoma 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Meningeal Neoplasms 1Lymphoma 1Liver Neoplasms 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

vandetanib 7Sorafenib 6Magnetic Resonance Spectroscopy 6lenvatinib 5cabozantinib 5Sunitinib 4Iodine-131 4selpercatinib 3AZD 6244 3trametinib 2tipifarnib 2durvalumab 2dabrafenib 2alectinib 2Triiodothyronine 2Thyroxine 2Thyrotropin Alfa 2Paclitaxel 2Nivolumab 2Ipilimumab 2Fluorodeoxyglucose F18 2Everolimus 2Bortezomib 2Axitinib 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2tremelimumab 1temsirolimus 1tanespimycin 1sapanisertib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thyroid Neoplasms × sapanisertib × Clear all
NCT02244463 2024-01-12

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Dana-Farber Cancer Institute

Phase 1/2 Completed
46 enrolled 18 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡